uniQure Announces Dosing of First Patient in Phase III Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
DLRHX Fund | USD 27.37 0.02 0.07% |
Slightly above 61% of Delaware Healthcare's investor base is looking to short. The analysis of overall sentiment of trading Delaware Healthcare Fund mutual fund suggests that many investors are alarmed at this time. Delaware Healthcare's investing sentiment can be driven by a variety of factors including economic data, Delaware Healthcare's earnings reports, geopolitical events, and overall market trends.
Delaware |
LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 -- uniQure N.V. , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the Phase III clinical trial of AMT-162 for the treatment of amyotrophic lateral sclerosis caused by mutations in superoxide dismutase 1 , a rare, inherited and progressive motor neuron disease. EPISOD1 is a Phase III multi-cent
Read at finance.yahoo.com
Delaware Healthcare Fundamental Analysis
We analyze Delaware Healthcare's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Delaware Healthcare using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Delaware Healthcare based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Five Year Return
Five Year Return Comparative Analysis
Delaware Healthcare is currently under evaluation in five year return among similar funds. Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
Delaware Healthcare Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Delaware Healthcare mutual fund to make a market-neutral strategy. Peer analysis of Delaware Healthcare could also be used in its relative valuation, which is a method of valuing Delaware Healthcare by comparing valuation metrics with similar companies.
Peers
Delaware Healthcare Related Equities
OCLGX | Optimum Large | 0.78 | ||||
OCIEX | Optimum International | 0.63 | ||||
WASAX | Ivy Asset | 0.52 | ||||
OCFIX | Optimum Fixed | 0.34 | ||||
IMAAX | Ivy Apollo | 0.31 | ||||
WSGAX | Ivy Small | 0.28 | ||||
OCLVX | Optimum Large | 0.24 | ||||
OASGX | Optimum Small-mid | 0.16 | ||||
OASVX | Optimum Small-mid | 0.13 | ||||
OCSGX | Optimum Small-mid | 0.13 |
Other Information on Investing in Delaware Mutual Fund
Delaware Healthcare financial ratios help investors to determine whether Delaware Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Delaware with respect to the benefits of owning Delaware Healthcare security.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |